As­traZeneca, Dai­ichi Sanky­o's ADC En­her­tu blows away Roche's Kad­cy­la in sec­ond-line ad­vanced breast can­cer

As­traZeneca and Japan­ese drug­mak­er Dai­ichi Sankyo think they’ve struck gold with their next-gen ADC drug En­her­tu, which has shown some strik­ing da­ta in late-stage breast can­cer tri­als and ear­ly sol­id tu­mor tests. Get­ting in­to ear­li­er pa­tients is now the goal, start­ing with En­her­tu’s com­plete walkover of a Roche drug in sec­ond-line breast can­cer re­vealed Sat­ur­day.

En­her­tu cut the risk of dis­ease pro­gres­sion or death by a whop­ping 72% (p=<0.0001) com­pared with Roche’s ADC Kad­cy­la in sec­ond-line un­re­sectable and/or metasta­t­ic HER2-pos­i­tive breast can­cer pa­tients who had pre­vi­ous­ly un­der­gone treat­ment with a Her­ceptin-chemo com­bo, ac­cord­ing to in­ter­im da­ta from the Phase III DES­TINY-Breast03 head-to-head study pre­sent­ed at this week­end’s #ES­MO21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER